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Putting Families First: How the Opioid Epidemic is Affecting Children 
and Families, and the Child Welfare Policy Options to Address It 
 
Introduction 
 
For the first time in decades, the number of children in foster care is rising. 
The U.S. Department of Health and Human Services reported that there 
was a total of 442,995 children in foster care in federal Fiscal Year (FFY) 
2017.1 This number represents a dramatic increase over the 396,966 
children in foster care recorded in 2012.2,3 Even at the height of the crack 
cocaine epidemic in 1999, the number of children in foster care totaled 
567,000.  In 36 percent of cases in FFY 2017, parental drug use was a 
primary reason cited for the child’s removal from the family4 and parental 
drug use likely contributed as a reason for placement in many more cases. 
Parental substance use has long been recognized as a major contributor 
to child welfare involvement, and recent research supports the conclusion 
that the primary cause of the current increase in children entering foster 
care is the impact of the opioid epidemic on parents and caregivers.5 The 
U.S. Substance Abuse and Mental Health Services Administration 
estimates that nationally 400,000 births are affected by prenatal exposure 
to alcohol and illicit drugs, representing 10 percent of all live births,6 often  
resulting in child welfare involvement. The National Survey of Child and 
Adolescent Well-Being (NSCAW) estimates that 61 percent of infants and 
41 percent of older children in out-of-home care originate from families 
with active alcohol or drug abuse.7,8 This statistic likely underrepresents 
the impact of parental substance abuse, as 62 percent of children who 
enter foster care are placed because of neglect. In many instances, even 
when substance abuse is not ascertained or recorded, it is often a 
contributing factor to child welfare involvement.9,10 This nationwide 
increase has brought further strain on an already limited supply of quality 
family foster homes,11,12,13,14,15,16 and highlights a fundamental mismatch 
between child welfare policy and the needs of children and families.  
At its heart, the opioid epidemic is a crisis of disrupted parental 
attachment. Children who have parents with substance use disorders 
need healthy attachment bonds with their primary adult caregiver in order 
to grow, develop, and thrive. Foster care is a crucial therapeutic 
intervention that can address this need while helping to ensure the child’s 
safety and wellbeing but isn’t the only means to do so. Extensive services 
to treat parental substance use disorders and prevent the need for foster 
care, where safe and appropriate, can support healthy parent-child 
attachment within the family of origin without the additional trauma of 
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family disruption. Until recently, child welfare policy has not sufficiently 
promoted this treatment model. 
Over the past several decades, policymakers have enacted several 
substantial improvements to child welfare policy, including the promotion 
of kinship caregiving and expanded efforts to oversee and coordinate the 
health needs of children in foster care. During this time, child welfare 
practice has come to recognize and address the trauma history and 
treatment needs of all family members.  With this expanded understanding 
of the effects of past trauma in the lives of parents as a cause of and 
contributing factor to child maltreatment, the child welfare field has shifted 
toward ensuring the safety of the child while seeking to prevent the need 
for foster care by serving the whole family. While this paradigmatic shift 
has been vital to changing attitudes and practices, the incentive structure 
in current child welfare policies has focused most federal child welfare 
funding solely on foster care placement while failing to support these more 
innovative policy alternatives.  
Current federal child welfare policies incentivize removals from 
families to foster care placement. Foster care placement can be 
necessary for the safety of the child and can serve as a critical and 
therapeutic intervention. However, routine foster placement of children 
whose parents have substance use disorders is at odds with best 
practices for treatment for this population, results in further trauma for 
children and families, and is an inefficient use of limited resources. In 
many instances, affected children and families could receive treatment 
and support services that address the substance use disorder while also 
helping the family to heal together. Research findings about what is best 
for treating vulnerable families in crisis have spurred years of advocacy to 
enable states to use federal foster care funds for upstream services to 
prevent the need for foster care, including substance use disorder and 
mental health treatments for parents. Newly enacted policies in 2018 in 
the Family First Prevention Services Act offer an opportunity to shift those 
incentives and offer critical support to vulnerable children and families 
affected by parental substance use.17 
 This article will examine the impact of parental substance use, and 
particularly the opioid epidemic, on children and families. In addition, it will 
outline the most recent public data on parental substance use and child 
welfare, examine the latest research on how parental substance use 
contributes to disrupted attachment, present the latest research on how 
prenatal exposure to opioids affects children’s health and development, 
and outline research supporting the preservation of families when possible 
during treatment for substance use disorders. In particular, we will 
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examine key policy considerations and options for this issue, including 
implementation of the recently enacted Family First Prevention Services 
Act, that offer alternative approaches to serving children and families 
affected by the opioid epidemic. The identification of parental substance 
use disorders offers the opportunity to address unmet parental needs that 
may threaten a parent’s ability to care for their child or children while 
maintaining family stability. By supporting the resilience of families and 
equipping parents with the skills to successfully parent children, public 
policy can ensure children who have experienced prenatal substance 
exposure or parental substance use disorders have the safe, stable, 
nurturing relationships they need to thrive while also supporting the foster 
care system as a therapeutic safety net for the children who require 
placement.  
 
The Scope of the Problem 
The opioid epidemic has caused significant morbidity and mortality 
in the U.S. In 2016, drug overdoses of all kinds led to over 66,000 deaths, 
42,000 of which were from opioids.18 Overdose deaths are now causing 
more deaths than car crashes.19 The age-adjusted rate of drug overdose 
deaths has increased more than three times from 6.1 per 100,000 in 1999 
to 21.7 per 100,000 in 2017.20 Similarly, the age-adjusted opioid overdose 
death rate in 2016 was 13.3 per 100,000, reflecting a 28 percent increase 
from 2015.21 There are clear indications that substance use disorders also 
detrimentally affect families. 59 percent of adults in substance use 
programs are parents of minor children (i.e., over 1 million of the 1.84 
million in treatment) and 27 percent (294,000) have had 1 or more children 
removed by child welfare services. Other estimates suggest that up to 70 
percent of women in substance abuse treatment have children.22 
Substance use in pregnancy carries significant implications for 
maternal-child health. Results of the 2014 National Survey on Drug Use 
and Health showed that 5.4 percent of pregnant women were current illicit 
drug users. Between 2009 and 2012, women of reproductive age filled 
prescriptions for opioid medications at a rate of 27.7 percent for those who 
were privately insured, and 39.4 percent for those with Medicaid.23 From 
1992 to 2012, hospital admissions of pregnant women reporting 
prescription opioid abuse increased from 2 percent to 28 percent.24 This 
increase probably occurred because of better reporting and surveillance 
data as well as an actual increase in opioid use. Substance use in 
pregnancy is generally consistent across demographic groups with studies 
showing similar rates of substance use during pregnancy by women of 
different racial, socioeconomic status, and age. These increases are 
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emblematic of the rising opioid epidemic, representing a major child health 
challenge that necessitates serious policy considerations.  
As the opioid epidemic continues to negatively affect families, 
changes in the demographics of foster care suggest this trend are having 
even greater impact on child welfare systems across the country. In 
federal FY 2017, 269,690 children entered foster care, compared to 
251,352 in 2012. In 2017, children in foster care spent a median of 12.7 
months in out-of-home placement. In 36 percent of entries into foster care 
in 2017, states cited parental drug abuse as a circumstance associated 
with a child’s removal from their home, increasing slightly from the prior 
year.25 These figures likely undercount the proportion of families involved 
with the child welfare system where parental substance use is associated 
with child maltreatment. Intake screening is frequently incomplete and 
often failed to accurately characterize parental substance use as a 
contributing factor to the child’s removal.26 Previous studies have 
estimated that significant parental alcohol or substance use occurs in as 
much as 70 percent of families with children in protective custody, with 
highest rates in families with the youngest children.27 A recent study in 
Florida that found that a one standard deviation increase in statewide 
opioid prescribing was associated with 2,000 additional children entering 
foster care as a result of parental neglect.28 
Despite the even distribution of substance use across demographic 
categories, poor women and women of color are far more likely to be 
reported to health and child welfare authorities for use of substances 
during pregnancy than are other women. One study found that black 
newborns were four times more likely than white newborns to be reported 
to child protective services for prenatal substance exposure at the time of 
delivery.29 Chasnoff found that even though rates of drug use among 
pregnant women in a Florida county did not vary by race, African 
American women were 10 times more likely to be reported to social 
services for drug use compared with other groups.30 These structural 
racial and ethnic inequalities persist despite ongoing work in the child 
welfare field to address issues of racial bias, and point to a need to 
continue this work to ensure that decisions about child safety do not 
perpetuate harmful bias. 
The issue of parental substance use is one of many factors that 
determine whether to remove a child from their family. Substance use 
often occurs within the context of additional challenges to family stability, 
and child protection workers face a difficult task in balancing these risks to 
child safety with the benefits of family preservation and treatment. 
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Ultimately, parental substance use disorders threaten both children’s 
safety and their healthy attachment with their parents. 
 
The Threat of Parental Substance Use Disorder to Attachment and 
Child Development 
Developmental outcomes and parent-child attachments of children 
living in families with parental substance use disorders are complicated by 
well-documented barriers to accessing substance use disorder 
treatment.31,32 In 2017, infants represented 19 percent of all entries into 
foster care, totaling 50,076 infants. Children under age 3 represented one-
third of all entries into care, totaling 88,403 infants and toddlers who 
experienced removal from their birth families as a result of maltreatment.33 
This critical developmental period, from birth to 3 years of age, is essential 
to the establishment of a child’s secure attachment with their parent(s). 
This primary attachment relationship is fundamental to healthy brain 
development and is the template for all future relationships. It assumes the 
presence of a responsive, attuned caregiver who is consistently available 
in the child’s life.34 Separation from a parent during this time disrupts a 
relationship that marks the most important milestone for the development 
of trust, safety, self-esteem, and social skills that develop over the child’s 
life into adulthood.   
Adverse childhood experiences, including having a parent with a 
substance use disorder, can result in trauma that, unbuffered by parental 
warmth and attunement, contributes to alterations in early brain 
development and negative health, educational, and economic outcomes 
across the lifespan.35 In addition to impairments caused by drug and 
alcohol use, the extensive co-morbidity of depression and post-traumatic 
stress disorder among women with substance use disorders causes 
emotional distress that influences the quality of attachment as well as 
parental interactions with their child.36 In combination with their own 
substance use and limited social support, mothers recovering from 
addiction face extraordinary demands.37 Children may experience 
discontinuity of parental care through separations that occur with child 
welfare placement, substance use relapse, parental incarceration, and 
parents’ difficulty in being consistently physically and emotionally present 
in a way that is essential to healthy child attachment and development. 
The erratic mood swings, irritability, and feelings of shame that 
accompany addiction not only increase a parent’s risk of child 
maltreatment and child welfare involvement, but all too often undermine 
recovery from substance-dependence. Implementation of integrated 
programs that address both mothers’ and children’s needs recognize the 
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critical role of bonding in facilitating maternal recovery. Thus, treating 
mothers with substance use disorder and promoting secure attachment 
bonds are increasingly recognized as two interdependent components that 
promote restitution of families afflicted by substance use in the child 
welfare system.38 When this treatment plan is not safe, tenable, or 
desirable, quality kinship and high-quality family foster caregivers are 
invaluable therapeutic resources that can facilitate the development of 
secure attachment with new permanent caregivers.  
Research on trauma and adversity clearly shows it is possible to 
mitigate the effect of adverse childhood experiences with the right 
interventions and supports. Safe, stable, nurturing relationships with 
caring adults can transform a child’s life trajectory. Public policy has a vital 
role in facilitating reparation of attachment disrupted through parental 
substance use disorder. A critically important outcome for this population 
of children is a nurturing and attentive environment with a loving caregiver 
who is knowledgeable about the child’s needs. When possible, this can be 
with a birth parent who is receiving treatment and all necessary supports 
for parenting skills and meeting a child’s needs. That is true both for 
helping to heal a child’s disrupted attachment to support reunification with 
a birth parent when safe and appropriate, and also for helping prepare a 
child for permanency in a loving home through kinship, guardianship, or 
adoption.  
 
Maternal Risk Factors for Child Welfare Involvement 
Parental substance use, if untreated, has devastating effects upon 
families, particularly through its impact on child health and development. 
Maternal substance use places the mother’s health at risk even prior to 
conception. Women with substance dependence have higher rates of 
medical and social problems, including undiagnosed and/or untreated 
medical and psychiatric illnesses. They are also more likely to have been 
raised by parents who also suffered from addiction, to have been involved 
in the child welfare system as children, and to have experienced intimate 
partner violence, incarceration, homelessness, poverty, and malnutrition.39 
The estimated prevalence of post-traumatic stress disorder (PTSD) 
ranges from 20-60 percent among women in substance use treatment. In 
one study, more than 70 percent of women in substance use treatment 
reported a history of childhood sexual abuse, 89 percent of women in 
substance use treatment reported a history of interpersonal violence and 
70 percent reported a history of sexual assault, placing them at especially 
high risk for depression, PTSD, and sexual victimization.40 Finally, 
substance use is also associated with higher rates of sexually transmitted 
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infections and unplanned pregnancy. The majority of HIV infections in 
women in the United States can be traced to intravenous use of drugs or 
heterosexual contact with an intravenous drug user.41,42 Opioid-dependent 
women are more likely to use drugs with multiple partners and exchange 
sex for drugs than men. Because of the high rate of intravenous opioid 
use and sex-related risk patterns, 50 to 62 percent of opioid-dependent 
women are hepatitis C virus (HCV) positive, and between one and four 
percent are HIV positive.43 
Overall, studies indicate that women with substance dependency 
experience a high incidence of socioeconomic problems, criminal justice 
system involvement, histories of victimization, and mental and physical 
health problems. Chronic drug use, few financial resources, unstable 
housing, familial history of abuse, legal problems, problems with physical 
and mental health conditions, and lack of social support from family and 
friends all work to undermine a parent’s ability to care for their children. A 
study using data collected from mothers at intake to 50 publicly funded 
residential substance use disorder treatment programs for pregnant and 
parenting women found that most women admitted to these programs 
were unemployed (88.9 percent), lacked a high school degree or GED 
(51.7 percent), and relied on public assistance as a source of financial 
support (70.6 percent), although nearly one-third (31.9 percent) lived with 
a spouse or partner in the year prior to treatment entry. Maternal stress 
often leads to depression, anxiety and hostility that has a critical influence 
on children’s emotional and behavioral development.44 
Polysubstance use is highly prevalent among US reproductive-
aged women reporting nonmedical opioid use. Of women with children 
enrolled at an opioid treatment center, 91.4% of patients used two or more 
non-opioid maintenance substances. The most frequently used 
substances were heroin and/or non-opioid maintenance opiates (80%) 
followed by marijuana (54.3%), cocaine (47.1%), benzodiazepines 
(31.4%) and amphetamines (25.7%). 54.3% of patients reported use of 1–
9 cigarettes per day and 15.7% reporting use of 10 or more cigarettes per 
day. Half (50%) of the study population used alcohol sometime during 
pregnancy and 100 percent of women tested positive for alcohol 
metabolites at delivery, and poly-substance use (≥2 substances used) was 
found in the majority of women (91.4 percent).45 Similarly, a study by the 
National Institute on Drug Abuse found alcohol use disorders in 38 percent 
of opioid-using patients who sought treatment.46 More recent cross-
sectional studies report prevalence rates of 33 percent up to 50 
percent.47,48 The role of polysubstance use is an important yet often 
neglected consideration when discussing policies related to parental 
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opiate use and the developmental effects on children with these prenatal 
exposures. 
There has been a recent conceptual shift in our understanding of 
addiction and the needs of those suffering from substance use disorders. 
Research has begun to elucidate how early adverse experiences may 
induce long-lasting alterations in the dopamine system, the oxytocin 
system, and the glucocorticoid system at molecular, neuroendocrine, and 
behavioral levels. These changes can ultimately lead to heightened 
vulnerability to substance use disorders.49 Consideration of life 
experiences and the context this plays in addiction has led to a greater 
understanding of subsequent challenges in parenting. Furthermore, 
substance use may follow a chronic, relapsing course that undermines the 
physical and psychological well-being of the affected individual and the 
social supports that might otherwise help support recovery. Women who 
use alcohol in addition to opioids are more likely to relapse, yet treatment 
for alcohol use is often not identified during treatment for opioid 
addiction.50, 51  
The overlap between mental illness and co-occurring substance 
use associated with nonmedical opioid use by pregnant women supports 
policy efforts to improve mental health and trauma screening at the time of 
substance use treatment.52 Pregnancy is a unique opportunity to identify 
opioid dependence, facilitate conversion to opioid maintenance treatment, 
and coordinate care among specialists in addiction medicine, behavioral 
health and social services. Eligibility for Medicaid during pregnancy and 
the postpartum period also facilitates access to opioid replacement 
therapy, prenatal care and other necessary health care services for many 
otherwise uninsured high-risk women. In addition, this offers the child 
welfare system critical points for intervention, proactive supports and 
services to ensure the healthiest possible situation for an infant.53 Given 
the role maternal experiences of trauma and adversity play in contributing 
to increased risk of substance use disorder, it is important to ensure that 
interventions and public policy focus on treating these underlying 
contributing factors to promote healing and potential reunification.  
 
Neonatal Abstinence Syndrome (NAS) and Child Welfare 
Use of opioids by women of child bearing age can impact neonates 
before and after birth. Opioids are water soluble with low molecular 
weight, allowing them to cross the placenta and easily transfer from the 
mother to the fetus. As the gestational age of the fetus increases, transfer 
of opioid drugs through the placenta increases. Synthetic opioids and 
opioids combined with other drugs (such as cocaine) further increase the 
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ease of transfer to the fetus. These drugs easily cross the blood-brain 
barrier of the fetus.54 The developing fetus can be affected by exposure to 
drugs used by the mother during pregnancy. Sudden discontinuation of 
prolonged prenatal exposure to opioids at birth can lead to neonatal 
abstinence syndrome (NAS).  
NAS is a medical condition in which newborns exposed to opioids 
or other drugs in utero experience drug withdrawal. The pathophysiology 
of this problem is not completely understood but seems to hinge on 
increased production of multiple neurotransmitters, including 
norepinephrine,55 which reflect the impact on multiple body systems 
resulting in “disorganized rather than adaptive behaviors.” 56 These 
changes impair the infant’s ability to feed, sleep, be alert, and 
communicate cues to caregivers. Exposure to opioids by neonates can be 
detected by two methods: self-report by the mother and biological 
specimens, including urine, meconium, and hair testing.57 Both methods 
have potential for inaccuracies; with possible inaccurate self-report by the 
mother, and timing and detection sensitivity threshold concerns in 
biological specimens.   
Symptoms of neonatal abstinence syndrome, such as 
hyperirritability, tremors, excessive crying, diarrhea, feeding problems, 
vomiting, and seizures, typically present within 36-60 hours of birth,58 
depending on the specific opioid and/or other substance exposure. After 
1-2 weeks, these symptoms usually wane and are replaced by a more 
chronic relapsing remitting course of symptoms including sleep 
disturbances, over eating, and hyper-irritability that can last for months.59  
The symptoms of neonatal abstinence syndrome can make a newborn 
infant difficult to console and care for and may increase parental stress. All 
of these challenges necessitate thoughtful policy considerations of how to 
support mothers who continue to care for their infants.60 
Infants born to mothers who use heroin, prescription opioids, or 
medication-assisted treatment (MAT) for opioid use disorders, as well as 
those using other substances are at risk for withdrawal symptoms 
following delivery.61 In a large study of 112, 029 pregnant women in 
Tennessee, 28% of pregnant women filled more than one opioid 
prescription.62 The use of prescribed versus non-prescribed opioid use 
varies geographically even within the same state. The Tennessee 
Surveillance System for Neonatal Abstinence Syndrome confirmed NAS 
rates of 25.5 per 1,000 live births in 2013 and 28.5 per 1,000 live births in 
2014. Mothers of NAS infants in eastern Tennessee were more likely than 
mothers of NAS infants in the state overall to use prescription medications 
obtained without a prescription.63 While in utero opioid exposure can be 
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harmful, medication-assisted treatment is highly effective at supporting 
improved pregnancy and birth outcomes and is safer than going through 
opioid withdrawal during pregnancy. Methadone treatment has been 
shown to be beneficial in predicting the discharge custody status of the 
neonate as well as engagement with antenatal care that reduces the 
likelihood of preterm birth and is independently associated with the 
neonate being discharged to the care of the mother. 
Buprenorphine treatment of maternal opioid use disorder is associated 
with lower risk of preterm birth, greater birth weight and larger head 
circumference compared with methadone treatment. These findings 
indicate that medication-assisted treatment has a significant role to play in 
facilitating parental recovery, infant safety, and long-term family health.64   
With the increasing trends in maternal substance use, there has 
been a parallel rise in the incidence of neonatal abstinence syndrome. 
Incidence of the disorder has risen sharply since 2000 as the opioid crisis 
has increasingly affected the United States. From 2004 to 2014, the 
incidence increased fivefold, from 2.8 to 14.4 per 1000 hospital births.65 
Current estimates suggest that a child is born with neonatal abstinence 
syndrome approximately every 15 minutes.66 Some geographic variability 
has been noted, with highest rates of the NAS in New England and the 
East South-Central States and lowest rates in the West South-Central 
states. This geographic variability correlates with opioid-prescribing 
patterns in the states, with states with higher prescribing patterns seeing 
higher rates of neonatal abstinence syndrome.67 
The common perception of substance abuse as a problem of poor, 
inter-urban individuals has been demonstrated to be inaccurate regarding 
NAS. The proportion of infants diagnosed with NAS who were from rural 
counties increased from 12.9 percent in 2003 to 21.2 percent in 2013. 
From 2004 to 2013, the incidence increased from 1.2 to 7.5 per 1000 
hospital births among rural infants and from 1.4 to 4.8 per 1000 hospital 
births among infants in urban hospitals. Similarly, during the same period, 
the frequency of hospital deliveries complicated by maternal opioid use 
increased from 1.3 to 8.1 per 1000 hospital deliveries among mothers in 
rural areas and from 1.6 to 4.8 per 1000 hospital deliveries among 
mothers in urban areas.68 
Management of NAS includes non-pharmacological care, such as 
continuous minimal stimulation and frequent high-calorie feeds, rooming-
in, and breastfeeding when indicated. When necessary, treatment can 
also include pharmacological care with opioid therapy, such as morphine, 
methadone, or buprenorphine, and sometimes with adjunct drug therapy 
such as phenobarbital, clonidine, and diazepam. Pharmacological care is 
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typically reserved for infants not responding to non-pharmacological 
therapy or for those with severe symptoms, such as seizures.69 
Responding to mothers of infants with NAS with a nonjudgmental 
and caring approach may encourage maternal participation in care of the 
infant, which has been found to be the best form of non-pharmacological 
care for such infants.70 This is vital to effectively engaging mothers and 
preventing avoidable family disruption. Maximizing non-pharmacologic 
care reduces the need for pharmacologic care, which in turn can reduce 
length of hospitalization and associated costs. Two interventions for 
mothers that have been found to be effective in managing neonatal 
abstinence syndrome are rooming-in and breastfeeding when appropriate. 
A recent systematic review and meta-analysis found that rooming-in for 
infants with this problem was associated with reduced need for 
pharmacological treatment and shorter hospital stays, compared to 
standard neonatal intensive care unit (NICU) admission.71,72 Breastfeeding 
an infant with neonatal abstinence syndrome can also significantly reduce 
need for pharmacological therapy and decrease length of hospitalization.73 
The treatment of newborns with NAS has increased Medicaid 
charges and costs due to more complicated and longer hospital stays. 
Infants with this syndrome face an average hospital stay of 16 days. That 
can extend as long as 23 days for those requiring pharmacological care. 
This is compared to two to three days for uncomplicated full-term infants. 
In 2012, infants treated non-pharmacologically for neonatal abstinence 
syndrome had hospital charges on average of $66,700 per hospitalization, 
while infants treated pharmacologically for the disorder had hospital 
charges of $93,400 per hospitalization. In comparison, the standard 
charge for a full-term infant without this complication totaled $3,500 per 
birth.  With the increased incidence of babies born with this syndrome, 
total hospital charges for NAS have doubled from $732,000,000 in 2009 to 
$1,449,000,000 in 2012.74 It is important to note that this analysis does not 
consider professional charges or outpatient follow up costs for long term 
monitoring of infants with the disorder and therefore underestimates the 
total costs to Medicaid.  
The etiology of neonatal abstinence syndrome varies, based on   
the substances a mother may be using and the circumstances in which 
she is using them. These are important considerations for developing 
effective interventions and public policy. Intervention and policy efficacy 
will vary widely depending on whether it is applied to mothers with active 
substance use disorders and no treatment, those with a history of opioid 
use who are receiving medication-assisted treatment, and those who do 
not have an substance use disorder but are appropriately prescribed a 
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medication that leads to NAS. Polysubstance use can also affect NAS and 
its treatment. In order to craft effective responses to the issue, it is 
essential to define the various causal factors for NAS to ensure that an 
individualized approach will support maternal-child health outcomes for 
each family. Supporting mothers of infants with NAS is especially vital, 
given the challenges women with substance use disorder face, including 
their history of trauma, substance use disorder, and mental health 
treatment needs. These challenges, combined with the parenting 
difficulties that infants with NAS pose, necessitate thoughtful engagement 
and ongoing maternal support. For those situations where child welfare 
removes an infant to a kinship or family foster care setting, training, 
supports, and services will be vital policy considerations to preclude 
placement disruptions and promote healthy infant attachment. Whether an 
infant goes home with his or her mother or ends up with kin or in a family 
foster home, policy change can ensure that infants receive the quality 
parenting they need by focusing on inculcating healthy attachment.  
These considerations can guide the application of these larger 
principles by emphasizing treatment and family preservation with the 
overarching need to ensure child safety. The complicated reality is that 
there is no single intervention which can serve all affected families. Child 
welfare agencies face difficult decisions each day about how best to serve 
children and families affected by parental substance use disorders. When 
policies can equip and empower child welfare agencies with resources 
and tools to make informed decisions about individual cases, children and 
families will be able to receive more tailored and effective care and 
services.  
Keeping mothers and infants with neonatal abstinence syndrome 
together improves health outcomes if child welfare and health 
professionals can assure the child’s safety. Increasing numbers of 
programs are finding success for both mother and infant when they can be 
treated together in a comprehensive dyadic model that allows for the 
mother’s recovery from opioid addiction while meeting the infant’s needs. 
These programs find decreased hospital stays, decreased need for 
pharmacological care, and decreased costs without adverse events.75 
Having child welfare involved in this decision-making process allows 
opportunities for the provision of preventive services, such as high-quality, 
evidence-based, trauma-informed mental health services and substance 
use disorder treatment, while also monitoring and ensuring the child’s 
safety. 
 
Effect of Opioids on the Developing Central Nervous System  
12
Journal of Applied Research on Children:  Informing Policy for Children at Risk, Vol. 9 [2018], Iss. 1, Art. 4
https://digitalcommons.library.tmc.edu/childrenatrisk/vol9/iss1/4
   
 
   
 
Children with histories of prenatal substance exposure have an 
increased risk of poorer developmental outcomes than non-prenatally 
exposed children. There are also significant additional risk factors, such as 
poverty, homelessness, exposure to domestic violence, and neglect of 
other children in the home. Children of mothers with substance use 
disorders are at three times greater risk for being born prematurely, over 
three times more likely to be born small for gestational age, and nine times 
more likely to be admitted to the neonatal intensive care unit.76,77,78 Each 
of these birth outcomes has its own associated risks for developmental 
delays and disability in addition to that of the prenatal exposure. A recent 
study of 3,713 opioid-dependent women found 20 percent of infants were 
born preterm compared with 7.7 percent preterm infant births in the 
general population. The infant mortality rate for prenatally exposed infants 
(12.21/1000 live births) is almost three-fold higher than the infant mortality 
rate (4.9/1000) of live births in the general population.79 
Research on the direct teratogenic effects of opioids on fetal 
neurodevelopment are conflicting, but overall suggests that prenatal 
exposure to opioids increases long-term health and developmental risks 
that necessitate early intervention and efforts to ensure affected children 
have the resources and supports they need to thrive.80 Human studies 
struggle to control for co-morbid prenatal exposure to substances in 
addition to opioids, such as alcohol, cannabis, cocaine, and other illicit 
drugs. In addition, differentiating between the effects of prenatal opioid 
exposure and later post-natal environmental experience upon child 
development complicates attempts to elucidate the neurodevelopmental 
effects of prenatal opioid exposure. Yet recent findings in both human and 
animal studies have begun to describe associations between prenatal 
opioid exposure and abnormalities in fetal neurodevelopment. Children 
exposed in utero to opioids not only have a two times greater risk of birth 
defects such as neural tube defects,81 but also are significantly more likely 
to be born with smaller head circumferences and microcephaly, a head 
circumference below the 3rd percentile.82,83 Methadone-exposed infants 
exhibit changes on diffuse-weighted MRI imaging that suggest altered 
maturation of neural connective tracts.84 In addition, studies have 
documented changes in the neuroendocrine hypothalamic-pituitary-
adrenal axis, and neurotransmitters such as norepinephrine, serotonin, 
acetylcholine, and dopamine.85 Abnormalities in the GABA (gamma-
aminobutyric acid) system, which is excitatory in the immature brain and 
required for normal brain development, can lead to excessive excitation 
and cell death during fetal brain development. The GABA system later 
functions in inhibitory control, and abnormalities in the GABA system may 
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help explain evidence of difficulties in attention and self-regulation and 
impulse control sometimes seen in children prenatally exposed to 
opioids.86 Opioid receptors are expressed in the fetal brain, and there is 
growing evidence for the endogenous opioid system as a regulator of 
neurogenesis, with inhibitory effects of opioids. Interference with this 
system by maternal opioid use may inhibit the normal maturation process 
of the developing brain. Results of multiple studies have shown reduced 
brain volumes after prenatal opioid exposure, including reduced basal 
ganglia, thalamus and cerebellar white matter volumes.87  
Significant impairments across domains of cognitive, psychomotor 
and behavioral outcomes are more prevalent in infants and preschool 
children with prenatal opioid-exposure.88,89 Opioid-exposed infants are 
significantly more likely to have neurodevelopmental impairment when 
assessed at 18 months and 3 years of age compared to healthy control 
infants.90,91 Problems with behavioral inhibition among 2-year-old children 
with prenatal opioid exposure predict later emotional and behavioral 
problems at age 4 ½ years.92 Hyperactivity and short attention span have 
been noted in toddlers prenatally exposed to opioids, and older exposed 
children have demonstrated memory and perceptual problems.93 Five to 
six-year-old children of mothers treated with buprenorphine for opioid 
maintenance therapy during pregnancy show evidence of visual motor and 
attention problems in performance on the WPPSI-R scales, major deficits 
in motor skills and memory abilities, and signiﬁcantly elevated levels of 
hyperactivity, impulsivity and attention problems on ADHD scales as 
assessed by their teachers.94 Many of the neurobehavioral sequelae of 
prenatal opioid exposure become more prevalent as a child advances 
through development and increasingly complex cognitive and adaptive 
expectations highlight disabilities that may not have been apparent at 
earlier ages.  
Deficits in working memory and inhibitory control at age 2 years 
predict conduct problems, hyperactivity, peer relationships, and total 
behavioral problems at age 4 ½ years.95 Emotional dysregulation in early 
childhood has been found to be a common precursor of later difficulties in 
attention, self-regulation and impulse control, social interactions and 
externalizing, and aggressive behavior. Such impairments can escalate to 
behavioral and emotional dysregulation that places adolescents at 
increased risk for substance use and criminal behavior.96 
Given the difficulties in research design and limitations of available 
data, it is difficult to say definitively what role neonatal abstinence 
syndrome specifically plays in contributing to increased risk for 
developmental and cognitive challenges. However, the extent of 
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correlative findings associating neonatal abstinence syndrome with these 
negative outcomes highlights a clear need to intervene early and support 
vulnerable children and families to facilitate the best possible outcomes.  
In a study of children diagnosed with neurobehavioral disorder 
following confirmed prenatal alcohol exposure, 83 percent of the mothers 
smoked and up to 67 percent used illicit drugs during pregnancy.97 
Mothers with opioid addiction use an average of 3.4 different drugs 
(including tobacco) during pregnancy and children born to mothers who 
used a higher number of different drugs during pregnancy have greater 
neurocognitive deficits that became more apparent over the course of 
childhood.98 These statistics highlight concurrent prenatal exposure to 
alcohol that is often missing in discussions of the current opioid epidemic. 
Fetal alcohol spectrum disorders have a prevalence of at least 1 percent 
to 5 percent in the general population, with much higher prevalence in the 
special populations of children in the child welfare and juvenile justice 
systems.99,100 The overlap between opioid and alcohol use in general, and 
specifically among pregnant women, means that the devastating 
neurodevelopmental consequences of fetal alcohol exposure will likely 
afflict many children with prenatal opioid exposure. Thus, prenatal opioid 
exposure not only increases the risk of neonatal abstinence syndrome but 
increases the risk of long-term neurodevelopmental disorders such as 
fetal alcohol spectrum disorders.101 The additive effect of these known 
neurotoxins on fetal brain development makes treatment of women with 
substance use disorders a priority to prevent future morbidity and costs 
associated with child disabilities that result from these prenatal 
exposures.102 
With further life adversities, children exposed to opioids become 
more likely to face increased developmental challenges.103 One of the few 
studies addressing the effects of cumulative environmental risk and 
prenatal substance exposure on young children’s development found that 
environmental risk accounted for more variance in developmental 
trajectories than prenatal drug exposure. Over time, the effects of 
environmental risk outweighed the adverse consequences of prenatal 
substance exposure. These findings confirm the importance of addressing 
risk factors in children’s environments associated with maternal substance 
use in treatment of both the mother and her child.104,105 
Early identification of children diagnosed with neonatal abstinence 
syndrome or history of prenatal opioid exposure allows attentive 
surveillance for developmental delay and referral to early intervention to 
minimize poor education and later life outcomes. Early Intervention 
services are available to all children ages 0-3 who meet state eligibility 
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criteria and are promoted in particular for children with child welfare 
involvement due to substantiated abuse and neglect through the Child 
Abuse Prevention and Treatment Act (CAPTA). Early intervention 
services, which utilize evidence-based interventions for developmental 
delay, have demonstrated outcomes including improved cognition, social-
emotional well-being, and school success.105 
 These services can be critical for addressing many of the 
developmental challenges that can arise in response to trauma and 
disrupted attachment. While all exposed children are eligible for these 
services through Part C of the Individuals with Disabilities Education Act 
(IDEA), there is insufficient funding to provide services for all affected 
children and access can be a challenge, particularly for children with child 
welfare involvement.106,107 Policymakers have a significant opportunity to 
increase resources to support expanded access to EI for children affected 
by parental substance use disorder. 
Pediatricians have a vital role in this effort, including through their 
role as a child’s medical home. Developed by the American Academy of 
Pediatrics, the medical home is a family-centered and integrative model of 
primary care delivery that ensures children’s primary care services are 
accessible, continuous, comprehensive, compassionate, and culturally 
effective. The medical home is a critical mechanism for coordinating and 
overseeing health services for children, and plays a critical role in 
addressing the needs of the whole family, making it an important 
intervention point to consider in addressing the relational health impact of 
parental substance use.108, 109 
Policy Considerations for Serving Families Affected by Parental 
substance use disorders 
The devastation of the opioid epidemic and what we know about 
how it affects maternal-child health and parent-child attachment provides 
policy opportunities for better serving families affected by parental 
substance use disorders, including: ensuring infant health and safety for 
infants prenatally exposed to substances; ensuring access to appropriate 
diagnosis and treatment of developmental and behavioral needs; ensuring 
parents have access to outpatient treatment and services that can allow 
families to stay together when safe and appropriate; providing access to 
effective treatments for pregnant women, including medication-assisted 
treatment, that can minimize fetal opioid exposure; and ensuring sufficient 
access to inpatient treatment options that can serve parents and children 
together while protecting an infant’s physical and emotional safety.  
Enacted in 2018 as part of the Bipartisan Budget Act of 2018,110 the 
Family First Prevention Services Act offers great promise to address many 
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of the ways that parental substance use affects children. Critically, this 
legislation will allow states an option to use open-ended funds under Title 
IV-E of the Social Security Act for time-limited evidence-based services to 
children and their parents or caregivers to prevent the need for foster care 
when a child is at imminent risk of entering foster care. These services 
include substance use disorder treatment, mental health services, and in-
home parenting skills training. These funds were previously limited 
primarily to payments for foster care, meaning that states availing 
themselves of this change could balance their current child welfare 
financing incentive structures to better prioritize treatment while keeping 
families together. 
This is a fundamental shift in the structure of U.S. child welfare 
policy. For the first time, federal law will enable child welfare agencies to 
use these resources not just for foster care, but for services that can help 
keep families together safely. There will always be instances in which 
children are better served by removal to foster care, either to eventually 
lead to safe reunification or to find safe and healthy permanency with a 
new family. High-quality kinship and non-relative foster care can change 
the trajectory of a child’s life and serve as a major therapeutic intervention. 
However, there are also many instances in which the types of services 
Family First will fund could help safely preserve families, so that children 
do not need to come into foster care and families can heal. These new 
permissible uses of Title IV-E funds comport with the extensive evidence 
presented above, which suggests that there are significantly improved 
maternal-child health outcomes when families receive treatment services 
that address their comprehensive needs.  
Without access to the types of services that will receive federal 
funding under Family First, placement in foster care has often been the 
appropriate response to a difficult situation. Absent services to safely 
prevent the need for foster care, the only option available to ensure 
children’s safety has been removal from their family of origin. This will 
remain an important option for ensuring child safety and promoting 
healing. But with these new services, child welfare agencies will have a 
wider continuum of options to consider as they assess the needs of 
individual families. This will allow for interventions that are better aligned 
with a family’s strengths, challenges, and needs. This will hopefully reduce 
the use of foster care for those children who can safely remain home while 
receiving services. In order to realize the promise of this new policy shift, 
states will have to affirmatively decide to use this new option under Title 
IV-E.  
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Family First embraces the core principle of avoiding unnecessary 
foster care by addressing the needs of families in crisis. This provides two 
significant improvements to help improve the sustainability of the child 
welfare system. First, those children who could remain safely at home with 
intensive services will no longer face the trauma of family removal. 
Second, this shift can help stem the rise in entries to foster care and make 
better use of current foster family resources. This means that for children 
who do need to enter foster care, there will be a greater likelihood of 
access to a quality foster home that can meet their needs. 
Another important aspect of these changes is that these services 
are available without regard to a family’s income. Access to Title IV-E 
maintenance payments is conditioned on the home from which a child is 
removed meeting the 1996 income eligibility requirements of the now-
defunct program Aid to Families with Dependent Children, the precursor 
the Temporary Aid to Needy Families program. Given that inflation makes 
it more difficult to meet those requirements each year, the federal share of 
foster care financing coverage has waned over time. Family First will offer 
a new service delivery pathway through this funding stream but without 
any income eligibility requirement. Instead, eligibility is tied to whether a 
child is at-risk for entering foster care absent receipt of these services. 
The program will both emphasize prevention of foster care placements 
when children can be safely served at home and expand the universe of 
eligible families. Effective implementation of these provisions will be 
critical to creating meaningful access to substance use disorder treatment 
services for families where children are at-risk of entering foster care. 
Since this policy is a state option, it also presents a significant 
consideration for state policymakers as they think through whether to 
participate in these services. In addition, it will be critical to develop the 
resource and services infrastructure necessary to effectively implement 
these policies. Federal policymakers will have a major opportunity to 
consider additional funding and supports to states to develop a pathway 
for states to develop a sufficient base of services for families, so that they 
may avail themselves of this major policy option for Title IV-E funded 
services.  
Family First also allows Title IV-E funds to support the placement of 
children in inpatient substance use disorder treatment settings with their 
parents when those settings can treat the needs of both the parent and 
child. This provision is also available without any income eligibility 
requirement. As noted above, the benefit of maintaining the mother-child 
dyad during treatment is associated with significant health outcome 
improvements for both the mother and child. Allowing this use of Title IV-E 
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funds means that child welfare systems will have new incentives to 
preserve families and seek access to treatment for pregnant and parenting 
women. Policymakers will also have the opportunity to consider how to 
further incentivize and support the development of more of these 
treatment settings, so that there is a sufficient supply of this placement 
option. Given that there are ongoing shortages of access to treatment in 
general, these types of specialized treatment settings are especially in 
need of support. This funding shift means that child welfare policy will now 
have incentives for following the best science on, where appropriate, 
keeping infants with their mothers during treatment. To make this a viable 
option, federal and state policymakers will have substantial decisions to 
make around how to ensure a sufficient stock of these treatment settings 
to meet community need. 
Family First also reauthorized the Regional Partnership Grant 
(RPG) program, which supports multidisciplinary approaches to 
addressing the impact of parental substance use on child welfare. The 
RPG program so far has included more than 15,000 families representing 
more than 25,000 children and 17,000 adults involved in the child welfare 
system. Outcomes showing children remaining at home or reunified with 
their parent(s) demonstrate a reduction of further maltreatment, a 
reduction in re-entry to the child welfare system, and increased levels of 
parents’ recovery.111 An example is the Kentucky Sobriety Treatment and 
Recovery Teams (START) program, which provides integrated treatment 
services for families with co-occurring substance use disorders and child 
maltreatment. Women in the program have shown higher sobriety rates 
(66 percent) than their child welfare-involved peers who were not receiving 
the START program (33 percent). The program also showed cost 
efficiencies, as each dollar spent on services resulted in savings of $2.22 
from avoided foster care placement costs.112 This integrative approach 
across programs and agencies ensures that parents and children are 
served through innovative collaboration that had not previously existed. 
States will have significant opportunities to consider how to develop 
sustainable systems providing these services. 
Another area for potential policy action is the promotion of quality 
foster parenting. Given the rising placements in foster care and the 
significant shortages of family foster homes, there are concerns around 
the country about how to serve affected children. When foster care is 
necessary for reasons of safety (physical, emotional and developmental), 
it is vital to ensure quality therapeutic intervention. The Academy of 
Pediatrics is a national partner in the nation Children Need Amazing 
Parents (CHAMPS) Campaign that seeks to create policy change in 20-25 
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states and federally that will promote quality parenting experiences for 
children in foster care.113 A critical aspect of this will be ensuring children 
have access to the health services they need to grow and thrive. Children 
in foster care have significant health needs, and managing and addressing 
those needs is a vital aspect of effective caregiving. The CHAMPS 
campaign presents opportunities to state and federal policymakers to 
consider how to best support foster, kin, and birth caregivers in meeting 
children’s needs and helping them access the services they need to heal.  
High-quality parenting is an essential therapeutic intervention for 
children who have experienced trauma, such as parental substance use 
disorders, and policies that support and empower quality caregiving will 
make a significant impact for children in foster care. To facilitate access to 
high-quality foster families, it is critical to support and empower foster 
parents so that they can understand the health needs of the children for 
whom they are caring. Ensuring foster parents have sufficient training in 
child trauma and development, as well as an understanding of the unique 
developmental and health needs of the child in their home, is vital to 
engaging them as partners in children’s care and recovery. Minnesota has 
enacted a law requiring all foster parents to be trained in caring for the 
special developmental needs of children with fetal alcohol spectrum 
disorders. Even with a significant emphasis on prevention and family 
preservation, there will always be children for whom placement in foster 
care is the appropriate outcome. The retention of quality foster parents, 
whether kinship or non-relative, will also be essential to helping children 
affected by parental substance use disorders heal and grow through the 
cultivation of healthy attachment.  
The enactment of the Affordable Care Act has expanded medical 
coverage to previously uninsured families and allowed women greater 
access to prenatal care. A recent study of nearly 3 million births found that 
the Affordable Care Act dependent coverage provision was associated 
with increased private insurance payment for birth, increased use of 
prenatal care, and a reduction in preterm birth. As women with substance 
use disorders are at risk for late or absent prenatal care, expanded access 
to care provides the opportunity for early intervention during pregnancy 
that utilizes universal substance use screening to link women to early 
opioid maintenance and addiction treatment. All of these opportunities are 
reliant upon access to quality prenatal care and drug treatment which are 
threatened by future erosions in coverage currently provided under the 
Affordable Care Act. 
Early identification of prenatal exposure and provision of access to 
services and safety assurances can help prevent future maltreatment and 
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child welfare involvement for children. Unless substance abuse is 
identified as a contributing factor to a child’s involvement with child 
welfare, there are few treatment programs that effectively address the 
combined needs of children and families.114 There is an urgent need to 
accurately measure the needs of this important subset of families that 
require treatment services before they enter the child welfare system, so 
that we can ensure they access appropriate services.  
The American College of Obstetrics and Gynecology recommends 
screening all women for substance use before and during early pregnancy 
and providing intervention when needed.115 Universal screening in 
pregnancy offers an opportunity to assess and refer pregnant women to 
treatment, to help improve maternal and child health outcomes. 
Pregnancy may be the only time that a woman presents for medical care 
and when an opioid use disorder can be identified and treated. Universal 
screening for substance use (alcohol, cigarette, illicit drugs, or prescription 
drugs without a prescription) during pregnancy is an additional option for 
early identification and intervention. Use of a validated screening tool 
administered in a nondiscriminatory, routine, and voluntary system can 
prevent discriminative testing and reporting to child welfare services.  
Furthermore, drug testing policies that deter women from seeking 
prenatal care are contrary to the welfare of the mother and fetus. 
Unfortunately, as of 2016, only 19 states had drug treatment programs 
specifically targeted to pregnant women, and only 12 provide pregnant 
women with priority access to state-funded drug treatment programs. A 
non-punitive approach avoids deterring women from seeking prenatal 
care. Once identified, it is vital that pregnant women with substance use 
disorders have access to treatment. This should include not just treatment 
of the substance use disorder, but also high-quality, evidence-based, 
trauma-informed mental health services as well that can address other co-
morbid challenges and contributing factors to the development of the 
substance use problem. Given what we know about maternal substance 
use disorders as a response to previous trauma and unmet treatment 
needs, policymakers have significant opportunities to expand access to 
treatments that address the root causes of this problem. 
The Child Abuse Prevention and Treatment Act (CAPTA) requires 
states to refer families to child welfare services if an infant is identified at 
birth is affected by prenatal substance exposure, withdrawal symptoms, or 
a Fetal Alcohol Spectrum Disorder (P.L.108-36).116 This provision was 
amended by the Comprehensive Addiction and Recovery Act of 2016, 
which expanded state reporting requirements but did not provide 
additional funds for development of plans of safe care. Given the role of 
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maternal trauma in driving parental substance use disorders, it will be 
critical for infant safety and long-term health and well-being to address not 
just maternal substance use disorders but also the underlying trauma and 
other risk factors. A plan of safe care can include early identification, 
screening, and engagement of pregnant women using substances, 
appropriate treatment for pregnant women, consistent hospital screening 
of mothers and their infants, consistent hospital notifications to the child 
welfare system, information sharing and monitoring across systems, and 
ongoing care plans for mothers and infants.117 This presents an 
opportunity to help both mother and child heal within their dyadic 
relationship, facilitating the development of healthy attachment. Funding 
and support for implementation of these provisions will be vital to 
supporting their translation into meaningful access to needed supports for 
affect families. In FY 2018 and FY 2019, Congress did appropriate $60 
million to support implementation of CAPTA plans of safe care. However, 
further and ongoing funding support will be critical for the operational 
success of this policy.  
Interdisciplinary interventions that combine the disciplines of 
substance use treatment, obstetrics/gynecology, trauma-informed mental 
health care, pediatrics and family planning to reduce barriers would 
promote healthy child development, save money, and help prevent entry 
into the child welfare system. Policymakers could provide sufficient funding 
to implement these plans of safe care requirements, along with 
appropriate technical assistance to ensure that all healthcare and child 
welfare personnel understand the intent and process for CAPTA plan of 
safe care requirements implementation. A recent U.S. Government 
Accountability Office report highlighted a lack of funding and technical 
assistance resources as impediments to implementation of these 
provisions.118 Rather than placing both mother and child under additional 
stress, the intent of this law is to facilitate services including a safe care 
plan for the child while providing support and treatment of the mother 
toward the goal of recovery from substance use and family preservation, 
reunification, or permanency with another family.119 As highlighted 
throughout this paper, such referral should attend not only to the treatment 
needs of the mother, but include ongoing and intensive developmental 
assessment and surveillance of the child and, when indicated, referral for 
intervention services.  
Family Treatment Drug Courts (FTDC) are an increasingly 
important strategy for addressing the needs of families involved with child 
welfare and impacted by substance use disorders. FTDCs have grown 
exponentially in the past two decades from only two programs in 1995 to 
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approximately 350 FTDCs in 2015. FTDCs provide structured support for 
the parent through expanded judicial oversight in conjunction with 
intensive intervention and treatment for parents’ substance use disorder 
and other comorbidity issues. Results show that FTDCs facilitate entry into 
substance use disorder treatment more quickly and promote longer and 
more consistent treatment and completion of treatment. Furthermore, 
children of parents who are participating in family treatment drug courts 
enter permanent placements more quickly and are more likely to be 
reunified with their parents, compared to children whose parents are not 
participants.120 Overseen by specially trained and dedicated judicial teams, 
these courts have the flexibility to administer a timely and intensive array 
of responses to the parents’ behavior and to improve their engagement in 
treatment and recovery support. Federally published guidelines suggest 
that such drug courts should bring together substance use disorder, 
mental health, social service, and other family-serving agencies to meet 
the needs of parents and their children.  
While historically family treatment drug courts have focused 
primarily on parent recovery from substance use, efforts have moved 
toward focus on additional services for children which improve outcomes 
for both parents and children. Services to children remain inadequate, as 
just over half (55.8 percent) of surveyed family drug courts indicated that 
they provided family-centered treatment or family-based services, and just 
51.2 percent indicated that they provide children’s services.121 This offers 
an opportunity for policies that promote expansion of this model in a way 
that addresses children’s needs. In particular, this should include effective 
engagement and coordination with a child’s medical home. The family 
drug court model represents the promise of focusing not just on the 
parent’s treatment needs and the child’s safety needs, but also on 
addressing and repairing the parent-child relationship to promote a healthy 
dyad. This is the essence of facilitating healthy attachment for those who 
might otherwise face removal from their family as the result of a parental 
substance use disorder.  
Family courts can also offer safety for women living in violent 
relationships. Evidence demonstrates that women who experience 
violence are more likely to be frequent users of substances, so preventing 
their exposure to violence can also provide a safe and stable context in 
which to heal and pursue recovery. After women become pregnant, the 
links between women’s experiences of intimate partner violence and their 
use of substances becomes stronger, with the women who experienced 
each type of partner violence being more likely to use both alcohol and 
illicit drugs. Furthermore, among the substance-using women, those who 
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are psychologically and physically abused have elevated levels of 
substance disorder symptoms during pregnancy compared with women 
who did not suffer such victimization. These findings underscore the 
importance of providing routine screening for various types of violent 
victimization and substance use within the context of many types of 
women’s health care settings, including substance abuse treatment 
programs, domestic violence programs, and prenatal care services.122 
   
Conclusion 
Parental substance use has a significant impact on children’s health and 
development, and is a leading factor for involvement in the child welfare 
system. Despite the role of parental substance use in driving rising 
numbers of children in foster care, evidence suggests that in many cases 
both children and parents can fare better through the receipt of intensive 
family preservation and substance use disorder treatment services, with 
appropriate child safety precautions. When it is unsafe for a child to 
remain safely with a parent with a substance use disorder, it is critical that 
the alternative caregiver be knowledgeable about the unique needs of a 
child who was prenatally exposed to a substance or who has a parent with 
a substance use disorder. All affected children need access to trauma-
informed care and appropriate support services, including developmental 
surveillance and early intervention when appropriate. The success of 
these services will also depend upon their coordination with a child’s 
medical home.  
There are significant policy opportunities to better serve this 
population of vulnerable children and families, most notably through 
effective federal and state implementation of the Family First Prevention 
Services Act. As policymakers explore opportunities to better serve 
children experiencing maltreatment, efforts to address the impact of 
parental substance use, and particularly the opioid epidemic, will be 
central to improving children’s health and well-being. Critical to that effort 
will be the understanding of the threat a parental substance use disorder 
poses to children’s health, development, and attachment. With additional 
tools available through prevention services and new treatment settings, it 
will be possible to consider how best to meet each affected child’s needs 
and promote healthy attachment so that he or she can heal and thrive.  
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